Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Weak
Balance Sheet
Very Strong
Telephone
61.3.8379.0100
Address
103-113 Stanley Street West Melbourne, Victoria (VIC) 3003
Description
Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The firm develops and commercializes pharmaceutical products using unique technology to administer drugs through the skin. Its products brands include AXIRON, ELLAVIE & EVAMIST and RECUVYRA. The company was founded by Ross Dobinson and Barrie Charles Finnin in 1998 and is headquartered in West Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.04 - 0.1
Trade Value (12mth)
AU$6,183.00
1 week
-9.23%
1 month
-10.61%
YTD
20.41%
1 year
34.09%
All time high
4.52
EPS 3 yr Growth
-65.20%
EBITDA Margin
-158.40%
Operating Cashflow
-$4m
Free Cash Flow Return
-53.60%
ROIC
-72.20%
Interest Coverage
N/A
Quick Ratio
1.60
Shares on Issue (Fully Dilluted)
290m
HALO Sector
Healthcare
Next Company Report Date
22-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
29 August 24 |
Appendix 4E and FY24 Full Year Statutory Accounts
×
Appendix 4E and FY24 Full Year Statutory Accounts |
29 August 24 |
Appendix 4G and Corporate Governance Statement FY24
×
Appendix 4G and Corporate Governance Statement FY24 |
29 August 24 |
FY24 Full Year Results - Investor Presentation
×
FY24 Full Year Results - Investor Presentation |
29 August 24 |
Investor Webinar Information - FY24 Results
×
Investor Webinar Information - FY24 Results |
27 August 24 |
FDA Approval received for Dapsone Gel, 7.5%
×
FDA Approval received for Dapsone Gel, 7.5% |
26 July 24 |
Quarterly Activities Report and Appendix 4C - June 2024
×
Quarterly Activities Report and Appendix 4C - June 2024 |
15 July 24 |
Acrux presentation to Bioshares, 18th Biotech Summit
×
Acrux presentation to Bioshares, 18th Biotech Summit |
28 June 24 |
RDTI funding facility secured
×
RDTI funding facility secured |
13 June 24 |
Acrux presentation at Hidden Gems in Lifesciences Forum
×
Acrux presentation at Hidden Gems in Lifesciences Forum |
30 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
30 April 24 |
Quarterly Activities and Appendix 4C, reissued
×
Quarterly Activities and Appendix 4C, reissued |
03 April 24 |
Launch of Dapsone 5%, Gel in the United States
×
Launch of Dapsone 5%, Gel in the United States |
05 March 24 |
Application for quotation of securities - ACR
×
Application for quotation of securities - ACR |
05 March 24 |
Appendix 3Y Brumley
×
Appendix 3Y Brumley |
05 March 24 |
Appendix 3Y Dobinson
×
Appendix 3Y Dobinson |
27 February 24 |
Appendix 4D and Half Year Accounts
×
Appendix 4D and Half Year Accounts |
27 February 24 |
Investor Presentation Half Year Accounts
×
Investor Presentation Half Year Accounts |
23 February 24 |
Investor Webinar Details - Financial Results 1H FY24
×
Investor Webinar Details - Financial Results 1H FY24 |
14 February 24 |
Notification regarding unquoted securities - ACR
×
Notification regarding unquoted securities - ACR |
14 February 24 |
Application for quotation of securities - ACR
×
Application for quotation of securities - ACR |
31 January 24 |
Appendix 4C and Activities Statement
×
Appendix 4C and Activities Statement |
20 December 23 |
Application for quotation of securities - ACR
×
Application for quotation of securities - ACR |
20 December 23 |
Appendix 3Y Brooke
×
Appendix 3Y Brooke |
20 December 23 |
Appendix 3Y Oldham
×
Appendix 3Y Oldham |
05 December 23 |
Notification regarding unquoted securities - ACR
×
Notification regarding unquoted securities - ACR |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.